Middle East and Africa Peptide Therapeutics Market to Grow at a CAGR of 6.5% to reach US$ 1,940.12 million from 2020 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Middle East and Africa Peptide Therapeutics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Middle East and Africa Peptide Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Growing Investments on Peptide Therapeutics

5.2 Market Opportunities

5.2.1 Operational Limitations of Peptides

5.3 Future Trends

5.3.1 Emphasis on Automatic Peptide Synthesis

5.4 Impact of Drivers and Restraints

6. Middle East and Africa Peptide Therapeutics Market Regional Analysis

6.1 Middle East and Africa Peptide Therapeutics Market Overview

6.2 Middle East and Africa Peptide Therapeutics Market Revenue 2017-2027 (US$ Million)

6.3 Middle East and Africa Peptide Therapeutics Market Forecast Analysis

7. Middle East and Africa Peptide Therapeutics Market Analysis – by Type

7.1 Generic

7.1.1 Overview
7.1.2 Generic: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Innovative

7.2.1 Overview
7.2.2 Innovative: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. Middle East and Africa Peptide Therapeutics Market Analysis – by Route of Administration

8.1 Parenteral

8.1.1 Overview
8.1.2 Parenteral: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Oral

8.2.1 Overview
8.2.2 Oral: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Mucosal

8.3.1 Overview
8.3.2 Mucosal: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Pulmonary

8.4.1 Overview
8.4.2 Pulmonary: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. Middle East and Africa Peptide Therapeutics Market Analysis – by Synthesis Technology

9.1 Solid Phase Peptide Synthesis

9.1.1 Overview
9.1.2 Pulmonary: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Liquid Phase Peptide Synthesis

9.2.1 Overview
9.2.2 Pulmonary: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Hybrid Technology

9.3.1 Overview
9.3.2 Pulmonary: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. Middle East and Africa Peptide Therapeutics Market – Middle East and Africa Analysis

10.1 Middle East and Africa

10.1.1 Middle East and Africa Peptide Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
10.1.1.1 Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 South Africa: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
10.1.1.1.2 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
10.1.1.1.3 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology

10.1.1.2 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
10.1.1.2.2 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
10.1.1.2.3 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology

10.1.1.3 UAE: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
10.1.1.3.2 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.3 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology

10.1.1.4 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
10.1.1.4.2 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
10.1.1.4.3 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Middle East and Africa Peptide Therapeutics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Amgen Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 EVER Pharma GmbH

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 AstraZeneca

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Bristol-Myers Squibb Company

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 GlaxoSmithKline plc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Novo Nordisk A/S

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Sanofi

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights